S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
Log in

5 killed in blaze at Indian producer of COVID-19 vaccine

Thursday, January 21, 2021 | Rafiq Maqbool, Associated Press


Smoke rises from the Serum Institute of India, the world's largest vaccine maker that is manufacturing the AstraZeneca/Oxford University vaccine for the coronavirus, in Pune, India, Thursday, Jan. 21, 2021. (AP Photo/Rafiq Maqbool)

PUNE, India (AP) — At least five people were killed in a fire that broke out Thursday at a building under construction at Serum Institute of India, the world’s largest vaccine manufacturer, officials said. The company said the blaze would not affect production of the COVID-19 vaccine.

Murlidhar Mohol, mayor of Pune city in southern Maharashtra state, said five bodies were found in the rubble after the flames were extinguished by firefighters.

Mahol said the victims were probably construction workers. He said the cause of the fire had not been determined and the extent of damage was not immediately clear.

Serum Institue of India's CEO, Adar Poonwala, said he was “deeply saddened” by the loss of life.

He said there would be no reduction in vaccine manufacturing because the company has other available facilities.

The company said the fire was restricted to a new facility it is constructing to increase the production of COVID-19 vaccines and ensure it is better prepared for future pandemics.

It said the fire did not affect existing facilities making COVID-19 vaccines or a stockpile of around 50 million doses.

Images showed huge plumes of smoke billowing from the building and dozens of company workers in lab suits leaving the compound as firefighters worked to extinguish the blaze.

Serum Institute of India is the world’s largest maker of vaccines and has been contracted to manufacture a billion doses of the AstraZeneca/Oxford University vaccine.

Poonawalla said in an interview with The Associated Press last month that it hopes to increase production capacity from 1.5 billion doses to 2.5 billion doses per year by the end of 2021. The new facility is part of the expansion.

Of the more than 12 billion coronavirus vaccine doses expected to be produced this year, rich countries have already bought about 9 billion, and many have options to buy even more. As a result, Serum Institute is likely to make most of the vaccines that will be used by developing nations.


7 Electric Vehicle (EV) Stocks That Have Real Juice

I’ll start with a disclaimer. You won’t see Tesla (NASDAQ:TSLA) or Nio (NYSE:NIO) on this list. And that’s not because I’m being contrarian. I just view Tesla and Nio as the known quantities in the electric vehicle sector. The goal of this presentation is to help you identify stocks that may be flying under your radar.

Many EV stocks went public in 2020 via a special purpose acquisition company (SPAC). There is both good and bad to that story. The good is that investors have many options for investing in the EV sector. Many of the companies that have entered the market are attempting to carve out a specific niche.

The potentially bad news is that these stocks are very speculative in nature. Whereas companies like Tesla and Nio have a proven (albeit recent) track record, there are things like revenue and orders that investors can analyze. With many of these newly public companies, investors are being asked to buy the story more than the stock and that is always risky.

However, in this special presentation, we’ve identified seven companies that look like they have a story that is compelling enough that investors should be rewarded in 2021.

View the "7 Electric Vehicle (EV) Stocks That Have Real Juice".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.